215 related articles for article (PubMed ID: 27914043)
1. A revisit to quantitative PET with
Akamatsu G; Ohnishi A; Aita K; Nishida H; Ikari Y; Sasaki M; Kohara N; Senda M
Ann Nucl Med; 2017 Feb; 31(2):163-171. PubMed ID: 27914043
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
4. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
5. Suite PET/CT neuroimaging for the diagnosis of Parkinson's disease: statistical parametric mapping analysis.
Wang R; Xu B; Guo Z; Chen T; Zhang J; Chen Y; Zhu H
Nucl Med Commun; 2017 Feb; 38(2):164-169. PubMed ID: 27893588
[TBL] [Abstract][Full Text] [Related]
6. Automated striatal uptake analysis of ¹⁸F-FDOPA PET images applied to Parkinson's disease patients.
Chang IC; Lue KH; Hsieh HJ; Liu SH; Kao CH
Ann Nucl Med; 2011 Dec; 25(10):796-803. PubMed ID: 21887536
[TBL] [Abstract][Full Text] [Related]
7. Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.
Sood A; Shukla J; Shree R; Vatsa R; Modi M; Mittal BR
Clin Nucl Med; 2021 Feb; 46(2):95-102. PubMed ID: 33234920
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
9. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
[TBL] [Abstract][Full Text] [Related]
11. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
12. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.
Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ
Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
15. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes.
Ma Y; Tang C; Chaly T; Greene P; Breeze R; Fahn S; Freed C; Dhawan V; Eidelberg D
J Nucl Med; 2010 Jan; 51(1):7-15. PubMed ID: 20008998
[TBL] [Abstract][Full Text] [Related]
16. Slowing of EEG waves correlates with striatal [
Lorek K; Mączewska J; Królicki L; Siemiatycka M; Chalimoniuk M; Kisiel-Sajewicz K; Marusiak J
Eur J Neurosci; 2023 Nov; 58(9):4070-4083. PubMed ID: 37787445
[TBL] [Abstract][Full Text] [Related]
17. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDOPA PET/CT imaging of insulinoma revisited.
Imperiale A; Sebag F; Vix M; Castinetti F; Kessler L; Moreau F; Bachellier P; Guillet B; Namer IJ; Mundler O; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):409-18. PubMed ID: 25367749
[TBL] [Abstract][Full Text] [Related]
19. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.
Cropley VL; Fujita M; Bara-Jimenez W; Brown AK; Zhang XY; Sangare J; Herscovitch P; Pike VW; Hallett M; Nathan PJ; Innis RB
Psychiatry Res; 2008 Jul; 163(2):171-82. PubMed ID: 18504119
[TBL] [Abstract][Full Text] [Related]
20. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
